$10995 | Single User
$21990 | Site License
$32985 | Enterprise License

PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024

Published by Global Data: 01 Oct 2015 | 17751 | In Stock

Introduction

PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024

Summary

In the 2014 base year, the global PAD market was worth approximately 3.4m, including both branded and generic drugs. By 2024, GlobalData expects that the global PAD market will experience significant expansion, with a Compound Annual Growth Rate (CAGR) of approximately 4.15%, equating to around 6.3m. The dramatic increase in the value of the overall global PAD therapeutics market will be partly attributable to the launch of several PAD drugs currently in late-stage pipeline development, which GlobalData believes have extraordinary potential. These include the novel antithrombotic pharmacological agents, Merck & Co.’s Zontivity (vorapaxar), AstraZeneca’s Brilinta (ticagrelor), and Bayer and Janssen’s (a subsidiary of Johnson & Johnson) Xarelto (rivaroxaban), which have the capacity to reform the antiplatelet and anticoagulatory PAD treatment landscape.

GlobalData believes that the size of the market for pharmacological agents designed to alleviate PAD symptoms, including cilostazol, naftidrofuryl, and pentoxifylline, will diminish throughout the forecast period. GlobalData accredits this diminishing to three factors: first, the advent of advanced revascularization procedures, as characterized by gradual, incremental improvements in success rates over time; second, the fact that current drug treatments, such as the ones mentioned above, display lackluster efficacy, perturbing safety attributes, and inconvenient dosing regimens; and third, the lack of novel, superior, premium-priced, drug therapies in the late stages of the PAD pipeline that could encroach on the patient shares of existing, rival pharmacological treatments.

The overall level of unmet need in the PAD market is high, resulting in a generous amount of room for new entrants to capitalize on. With respect to the first three traditional pillars of PAD treatment - antithrombotic pharmacological agents, lipid-lowering medical therapies, and antihypertensive drugs - the level of unmet need will fall once the current crop of late-phase PAD therapies portrayed in this report arrives onto the market. With respect to drugs that allay the symptoms of PAD, the level of unmet need here is astronomical. Present medical treatments are limited, archaic, and some have restricted availability.

Highlights

Key Questions Answered

- From a clinical standpoint, there is a demand for novel medical therapies that target and relieve the symptoms of PAD in IC and CLI patients. KOLs interviewed by GlobalData expressed a desire for second-generation drug treatments that display superior efficacy and favorable safety profiles compared to existing pharmacological. Environmental unmet needs for this particular indication include physician education, patient awareness, greater screening, and improved guidelines. What other unmet needs exist in this market? Will the drugs under development fulfil the unmet needs of the PAD market?

- The current late-stage PAD pipeline encompasses AstraZeneca’s Brillinta, Bayer/Janssen’s Xarelto and Merck’s Zontivity. Will the late-stage drugs make a significant impact on the PAD market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?

Key Findings

- The major drivers of this expansion in the PAD market will be the advent of novel antithrombotic agents, such as Brilinta and Xarelto, onto the PAD stage, and the increasing prevalence of PAD across all of the 8MM.

- The major global barrier to growth in the PAD market will be the losses of patent protection and market exclusivity on marketed and key pipeline drugs during the forecast period, such as AstraZeneca’s Crestor (rosuvastatin), Sanofi’s Plavix (clopidogrel), Brilinta, and Xarelto.

- The overall level of unmet need in the PAD market is high, resulting in a generous amount of room for new entrants to capitalize on. GlobalData forecasts that once Brilinta and Xarelto, pipeline pharmacological agents currently in late-stage clinical trials for PAD, navigate their way through the regulatory landscape and secure approval for the PAD indication, they will address some of the unmet needs in this area.

Scope

- Overview of peripheral artery disease (PAD), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

- Annualized PAD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PAD therapeutics market.

- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

- Analysis of the current and future market competition in the global PAD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

- Develop business strategies by understanding the trends shaping and driving the global PAD therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PAD therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Track drug sales in the global PAD therapeutics market from 2014-2024.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents
for PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024

  • 1 Table of Contents

    1 Table of Contents 12

    1.1 List of Tables 18

    1.2 List of Figures 22

    2 Introduction 25

    2.1 Catalyst 25

    2.2 Related Reports 26

    2.3 Upcoming Related Reports 26

    3 Disease Overview 27

    3.1 Etiology and Pathophysiology 28

    3.1.1 Etiology 28

    3.1.2 Pathophysiology 30

    3.2 Classification and Staging Systems 31

    3.3 Symptoms and Clinical Presentation 33

    3.4 Prognosis 37

    3.5 Quality of Life 41

    4 Epidemiology 43

    4.1 Disease Background 43

    4.2 Risk Factors and Comorbidities 44

    4.3 Global Trends 46

    4.4 Forecast Methodology 47

    4.4.1 Sources Used 48

    4.4.2 Sources Not Used 61

    4.4.3 Forecast Assumptions and Methods 61

    4.5 Epidemiological Forecast of Total Prevalent Cases of PAD (2014-2024) 67

    4.5.1 Total Prevalent Cases of PAD 67

    4.5.2 Age-Specific Total Prevalent Cases of PAD 68

    4.5.3 Sex-Specific Total Prevalent Cases of PAD 70

    4.5.4 Age-Adjusted Total Prevalence of PAD 72

    4.5.5 Total Prevalent Asymptomatic and Symptomatic Cases of PAD 73

    4.5.6 Total Prevalent Cases of PAD with Intermittent Claudication and PAD with Critical Limb Ischemia 75

    4.5.7 Proportion of Total PAD Cases that Present as Asymptomatic, PAD with Intermittent Claudication, and PAD with Critical Limb Ischemia 77

    4.5.8 Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes 78

    4.6 Epidemiological Forecast of Diagnosed Prevalent Cases of PAD (2014-2024) 80

    4.6.1 Diagnosed Prevalent Cases of PAD 80

    4.6.2 Age-Specific Diagnosed Prevalent Cases of PAD 82

    4.6.3 Sex-Specific Diagnosed Prevalent Cases of PAD 84

    4.6.4 Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD 86

    4.6.5 Diagnosed Prevalent Cases of PAD with Intermittent Claudication and PAD with Critical Limb Ischemia 88

    4.6.6 Proportion of Diagnosed PAD Cases that Present as Symptomatic, PAD with Intermittent Claudication, and PAD with Critical Limb Ischemia 90

    4.6.7 Diagnosed Prevalent Cases of PAD with Hypertension and PAD Cases with Diabetes 91

    4.7 Discussion 93

    4.7.1 Epidemiological Forecast Insight 93

    4.7.2 Limitations of the Analysis 94

    4.7.3 Strengths of the Analysis 95

    5 Disease Management 96

    5.1 Diagnosis and Treatment Overview 96

    5.1.1 Diagnosis 96

    5.1.2 Treatment Guidelines and Leading Prescribed Drugs 100

    5.2 US 101

    5.3 Five Major European Markets 108

    5.4 Japan 118

    5.5 Urban China 122

    6 Competitive Assessment 128

    6.1 Overview 128

    6.2 Lifestyle Modifications 132

    6.2.1 Exercise 132

    6.2.2 Smoking cessation 135

    6.3 Risk Factor Modification Drugs 137

    6.3.1 Lipid-Lowering Medical Therapies 137

    6.3.2 Antihypertensive Medical Therapies 144

    6.3.3 Antithrombotic Medical Therapies 151

    6.3.4 Glucose-Lowering Medical Therapies 172

    6.3.5 Thrombolytic Therapies 175

    6.4 Medical Therapies Treating the Symptoms of PAD - Major Brands 176

    6.4.1 Pletal / Pletaal (cilostazol) 176

    6.4.2 Praxilene (naftidrofuryl oxalate) 190

    6.4.3 Trental (pentoxifylline) 196

    6.4.4 Prostaglandin and Prostanoid Medical Therapies 205

    6.4.5 Other Pharmacological Therapies 209

    6.5 Non-Pharmacological Therapies 211

    6.5.1 Revascularization 211

    7 Unmet Need and Opportunity Analysis 217

    7.1 Overview 217

    7.2 Enhanced Patient and Physician Education and Awareness of PAD, Facilitating Augmented Diagnosis and Treatment Rates 219

    7.2.1 Unmet Need 219

    7.2.2 Gap Analysis 226

    7.2.3 Opportunity 228

    7.3 A Greater Number of Trials Exclusively Involving PAD Patients Will Yield Improved Guidelines for the Management of PAD 233

    7.3.1 Unmet Need 233

    7.3.2 Gap Analysis 237

    7.3.3 Opportunity 238

    7.4 Superior Pharmacological Agents that Treat the Symptoms of Intermittent Claudication and Critical Limb Ischemia, but also Obviate Cardiovascular Events 240

    7.4.1 Unmet Need 240

    7.4.2 Gap Analysis 242

    7.4.3 Opportunity 243

    7.5 Unravelling the Convoluted Nature Behind the Etiology and Pathophysiology of Atherosclerosis, Which Will Potentially Lead to Treatments that Prevent or Reverse Plaque Formation 247

    7.5.1 Unmet Need 247

    7.5.2 Gap Analysis 248

    7.5.3 Opportunity 248

    8 Pipeline Assessment 251

    8.1 Overview 251

    8.2 Promising Drugs in Late-Stage Clinical Development 253

    8.2.1 Xarelto (rivaroxaban) 254

    8.2.2 Brilinta (ticagrelor) 270

    8.3 Promising Drugs in Early-Stage Clinical Development 286

    8.3.1 Therapeutic Angiogenesis 286

    9 Current and Future Players 291

    9.1 Overview and Trends in Corporate Strategy 291

    9.2 Company Profiles 295

    9.2.1 Bayer 295

    9.2.2 Janssen (Johnson & Johnson) 297

    9.2.3 AstraZeneca 299

    9.2.4 Merck & Co. 302

    9.2.5 Sanofi 303

    9.2.6 Pfizer 305

    9.2.7 Bristol-Myers Squibb 306

    9.2.8 Otsuka Holdings 307

    10 Market Outlook 309

    10.1 Global Markets 309

    10.1.1 Forecast 309

    10.1.2 Drivers and Barriers - Global Issues 314

    10.2 US 318

    10.2.1 Forecast 318

    10.2.2 Key Events 322

    10.2.3 Drivers and Barriers 322

    10.3 Five Major European Markets 326

    10.3.1 Forecast 326

    10.3.2 Key Events 330

    10.3.3 Drivers and Barriers 331

    10.4 Japan 341

    10.4.1 Forecast 341

    10.4.2 Key Events 344

    10.4.3 Drivers and Barriers 344

    10.5 Urban China 347

    10.5.1 Forecast 347

    10.5.2 Key Events 350

    10.5.3 Drivers and Barriers 350

    11 Appendix 354

    11.1 Bibliography 354

    11.2 Abbreviations 382

    11.3 Methodology 387

    11.4 Forecasting Methodology 387

    11.4.1 Diagnosed PAD Patients 387

    11.4.2 Percent Drug-Treated Patients 388

    11.4.3 Drugs Included in Each Therapeutic Class 388

    11.4.4 Launch and Patent Expiry Dates 388

    11.4.5 General Pricing Assumptions 389

    11.4.6 Individual Drug Assumptions 390

    11.4.7 Generic Erosion 395

    11.4.8 Pricing of Pipeline Agents 395

    11.5 Physicians and Specialists Included in this Study 396

    11.6 About the Authors 400

    11.6.1 Analyst 400

    11.6.2 Therapy Area Director 400

    11.6.3 Epidemiologist 401

    11.6.4 Global Head of Healthcare 401

    11.6.5 Global Director of Therapy Analysis and Epidemiology 402

    11.7 About GlobalData 403

    11.8 Disclaimer 403

List Of Tables
in PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024

1.1 List of Tables

Table 1: The Various Causes of PAD 29

Table 2: The Rutherford-Baker System and the Fontaine Classification for PAD 32

Table 3: The Various Etiologies of ALI 33

Table 4: The Symptoms of PAD 37

Table 5: Risk Factors and Comorbidities for PAD 45

Table 6: 8MM, Sources of Epidemiological Data Used to Forecast the Total Prevalent Cases of PAD 48

Table 7: 8MM, Sources of Epidemiological Data Used to Forecast Symptomatic and Asymptomatic Total Prevalent Cases of PAD 49

Table 8: 8MM, Sources of Epidemiological Data Used to Forecast the IC and CLI Total Prevalent Cases of PAD 50

Table 9: 8MM, Sources of Epidemiological Data Used to Forecast Total Prevalent Cases of PAD with Hypertension or Diabetes 51

Table 10: 8MM, Sources of Epidemiological Data Used to Forecast the Diagnosed Prevalent Cases of PAD 52

Table 11: 8MM, Sources of Epidemiological Data Used to Forecast Asymptomatic and Symptomatic Diagnosed Prevalent Cases of PAD 53

Table 12: 8MM, Sources of Epidemiological Data Used for the Forecast of the Proportion of the Diagnosed PAD Population that Presents with IC 54

Table 13: 8MM, Sources of Epidemiological Data Used to Forecast Diagnosed Prevalent Cases of PAD with Hypertension or Diabetes 55

Table 14: 8MM, Total Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024 67

Table 15: 8MM, Age-Specific Total Prevalent Cases of PAD, Both Sexes, N (Row %), 2014 69

Table 16: 8MM, Sex-Specific Total Prevalent Cases of PAD, Ages ≥35 Years, N (Row %), 2014 71

Table 17: 8MM, Total Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N (Row %), 2014 74

Table 18: 8MM, Total Prevalent Cases of PAD with IC and PAD with CLI, Both Sexes, Ages ≥35 Years, N , 2014 76

Table 19: 8MM, Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N (Row %), 2014 79

Table 20: 8MM, Diagnosed Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024 81

Table 21: 8MM, Age-Specific Diagnosed Prevalent Cases of PAD, Both Sexes, N, 2014 83

Table 22: 8MM, Sex-Specific Diagnosed Prevalent Cases of PAD, Ages ≥35 Years, N (Row %), 2014 85

Table 23: 8MM, Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N (Row %), 2014 87

Table 24: 8MM, Diagnosed Prevalent Cases of PAD with IC or CLI, Both Sexes, Ages ≥35 Years, N , 2014 89

Table 25: 8MM, Diagnosed Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N (Row %), 2014 92

Table 26: Population Characteristics of Individuals who Require Regular Screening for PAD 96

Table 27: Treatment Guidelines for PAD 100

Table 28: 8MM, Most Prescribed Drugs for PAD by Class, 2015 101

Table 29: Country Profile - US 107

Table 30: Country Profile - 5EU 116

Table 31: Country Profile - Japan 121

Table 32: Country Profile - Urban China 125

Table 33: Leading Drugs for PAD Treatment, 2015 132

Table 34: 8MM, Most Frequently Prescribed Lipid-lowering Medical Therapies 143

Table 35: Most Frequently Used Beta Blockers 148

Table 36: Product Profile - Beta Blockers 149

Table 37: Most Frequently Used ACE Inhibitors 149

Table 38: Product Profile - ACE Inhibitors 150

Table 39: Most Frequently Used ARBs 150

Table 40: Product Profile - ARBs 151

Table 41: Product Profile - Plavix (clopidogrel) 155

Table 42: Product Profile - Zontivity (vorapaxar) 164

Table 43: Efficacy and Bleeding Endpoints at Three Years in the TRA 2P-TIMI 50 Study 165

Table 44: Product Profile - Metformin 174

Table 45: Product Profile - Pletal (cilostazol) 184

Table 46: Safety Profile - Pletal (cilostazol) 187

Table 47: SWOT Analysis of Pletal, 2015 188

Table 48: Global Sales Forecast ($m) for Cilostazol, 2014-2024 189

Table 49: Product Profile - Praxilene (naftidrofuryl) 193

Table 50: Safety Profile - Praxilene (naftidrofuryl) 194

Table 51: SWOT Analysis of Praxilene, 2015 195

Table 52: Global Sales Forecast ($) for Naftidrofuryl, 2014-2024 196

Table 53: Product Profile - Trental (pentoxifylline) 200

Table 54: Most Frequently Recorded Side Effects for Pentoxifylline and Cilostazol. 202

Table 55: The Incidence (%) of Side Effects with Trental 203

Table 56: SWOT Analysis of Trental, 2015 204

Table 57: Global Sales Forecast ($m) for Pentoxifylline, 2014-2024 205

Table 58: Indications for Revascularization in PAD 216

Table 59: Major Unmet Needs and Opportunities in PAD 219

Table 60: Promising Drugs in Late-stage Clinical Development in the PAD Pipeline, 2015 253

Table 61: Comparison of Therapeutic Classes in Development for PAD, 2015 254

Table 62: Product Profile - Xarelto (rivaroxaban) 262

Table 63: SWOT Analysis of Xarelto, 2015 268

Table 64: 8MM, Sales Forecast ($m) for Xarelto, 2014-2024 269

Table 65: Product Profile - Brilinta (ticagrelor) 280

Table 66: Brilinta’s Efficacy and Safety Endpoints as Three-Year Kaplan-Meier Estimates in the PEGASUS-TIMI 54 Study 281

Table 67: SWOT Analysis of Brilinta, 2015 285

Table 68: 8MM, Sales Forecast ($) for Brilinta, 2014-2024 286

Table 69: 8MM, Key Companies’ Relevant Key Marketed and Pipeline Drugs in the PAD Market, 2015 294

Table 70: Bayer’s PAD Portfolio Assessment, 2015 297

Table 71: Janssen’s PAD Portfolio Assessment, 2015 299

Table 72: AstraZeneca’s PAD Portfolio Assessment, 2015 301

Table 73: Merck’s PAD Portfolio Assessment, 2015 303

Table 74: Sanofi’s PAD Portfolio Assessment, 2015 304

Table 75: Pfizer’s PAD Portfolio Assessment, 2015 305

Table 76: Bristol-Myers Squibb’s PAD Portfolio Assessment, 2015 307

Table 77: Otsuka Pharmaceutical’s PAD Portfolio Assessment, 2015 308

Table 78: 8MM Sales Forecast ($m) for PAD, 2014-2024 311

Table 79: 8MM, PAD Market - Drivers and Barriers, 2015 314

Table 80: 8MM, Sales Forecast ($m) for PAD in the US, 2014-2024 320

Table 81: Key Events Impacting Sales for PAD in the US, 2014-2024. 322

Table 82: US PAD Market - Drivers and Barriers, 2014-2024. 322

Table 83: Sales Forecast ($m) for PAD in the 5EU, 2014-2024 327

Table 84: Key Events Impacting Sales for PAD in the 5EU, 2014-2024 330

Table 85: 5EU PAD Market - Drivers and Barriers, 2014-2024 331

Table 86: Sales Forecast ($m) for PAD in Japan, 2014-2024 342

Table 87: Key Events Impacting Sales for PAD in Japan, 2014-2024 344

Table 88: PAD Market - Japan Drivers and Barriers, 2014-2024 344

Table 89: Sales Forecasts ($m) for PAD in Urban China, 2014-2024 348

Table 90: Key Events Impacting Sales for PAD in China, 2014-2024 350

Table 91: China PAD Market -Drivers and Barriers, 2014-2024 350

Table 92: Abbreviations 382

Table 93: Key Launch Dates 388

Table 94: Key Patent Expiries 389

Table 95: High-Prescribing Physicians Non-KOLs Surveyed, By Country 399

List Of Figures, Charts and Diagrams
in PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024

1.2 List of Figures

Figure 1: Clinical Manifestations of PAD 28

Figure 2: Progression of PAD, Atherosclerotic Plaque Rupture and Thrombosis. 30

Figure 3: 8MM, Patient Flow for the Epidemiological Forecast of PAD 48

Figure 4: 8MM, Total Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024 68

Figure 5: 8MM, Age-Specific Total Prevalent Cases of PAD, Both Sexes, N, 2014 70

Figure 6: 8MM, Sex-Specific Total Prevalent Cases of PAD, Ages ≥35 Years, N, 2014 72

Figure 7: 8MM, Age-Standardized Total Prevalence of PAD, 2014 73

Figure 8: 8MM, Total Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N, 2014 75

Figure 9: 8MM, Total Prevalent Cases of PAD with IC and PAD with CLI, Both Sexes, Ages ≥35 Years, N, 2014 77

Figure 10: 8MM, Proportion of Total PAD Cases that Present as Asymptomatic, PAD with IC, and PAD with CLI, Both Sexes, Ages ≥35 Years, % 78

Figure 11: 8MM, Total Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N, 2014 80

Figure 12: 8MM, Diagnosed Prevalent Cases of PAD, Both Sexes, Ages ≥35 Years, Select Years, 2014-2024 82

Figure 13: 8MM, Age-Specific Diagnosed Prevalent Cases of PAD, Both Sexes, N, 2014 84

Figure 14: 8MM, Sex-Specific Diagnosed Prevalent Cases of PAD, Ages ≥35 Years, N, 2014 86

Figure 15: 8MM, Diagnosed Prevalent Asymptomatic and Symptomatic Cases of PAD, Both Sexes, Ages ≥35 Years, N, 2014 88

Figure 16: 8MM, Diagnosed Prevalent Cases of PAD with IC or CLI, Both Sexes, Ages ≥35 Years, N, 2014 90

Figure 17: 8MM, Proportion of Diagnosed PAD Cases that Present as Asymptomatic, PAD with IC, and PAD with CLI, Both Sexes, Ages ≥35 Years, %, 2014 91

Figure 18: 8MM, Diagnosed Prevalent Cases of PAD with Hypertension and PAD with Diabetes, Both Sexes, Ages ≥35 Years, N, 2014 93

Figure 19: The Most Common Tests Used to Diagnose PAD in US Patients, 2014 103

Figure 20: Breakdown of US PAD Patients by Percentage (%) Predominantly Treated in Primary or Specialist Healthcare Settings, 2014 104

Figure 21: The Most Common Tests Used to Diagnose PAD in 5EU Patients, 2014 112

Figure 22: Breakdown of 5EU PAD Patients by Percentage (%) Predominantly Treated in Primary or Specialist Healthcare Settings, 2014 113

Figure 23: The Most Common Tests Used to Diagnose PAD Patients in Japan, 2014 119

Figure 24: Percentage (%) Breakdown of Japan PAD Patients by Percentage (%) Predominantly Treated in Primary or Specialist Healthcare Settings, 2014 120

Figure 25: The Most Common Tests Used to Diagnose PAD Patients in China, 2014 123

Figure 26: Breakdown of Chinese PAD Patients by Percentage (%) Predominantly Treated in Primary or Specialist Healthcare Settings, 2014 124

Figure 27: 8MM, Percentage (%) of PAD Patients Referred to Specialist Secondary or Tertiary Care by Primary Care Physicians, 2014 127

Figure 28: The Various Marketed and Pipeline Antithrombotic Medical Therapies for PAD 152

Figure 29: The Treatment Algorithm for IC Patients 169

Figure 30: The Treatment Algorithm for CLI Patients 170

Figure 31: The Treatment Algorithm for ALI Patients 171

Figure 32: Competitive Assessment of Late-Stage Pipeline Agents in PAD, 2014-2024 253

Figure 33: Company Portfolio Gap Analysis in PAD, 2014-2024 295

Figure 34: Global Sales for PAD by Region, 2014 and 2024 312

Figure 35: 8MM, Global PAD Sales by Drug Class, 2014 and 2024 313

Figure 36: Sales for PAD in the US by Drug Class, 2014 and 2024 321

Figure 37: Sales for PAD in the 5EU by Drug Class, 2014 and 2024 329

Figure 38: Sales for PAD in Japan by Drug Class, 2014 and 2024 343

Figure 39: Sales for PAD in China by Drug Class, 2014 and 2024 349

Additional Details

Publisher

Global Data

Publisher Information

Reference

17751 | GDHC118PIDR

Number of Pages

404

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025
PharmaPoint: Heart Failure - Global Drug Forecast and Market Analysis to 2025SummaryGlobalData estim...
01 May 2016 by Global Data USD $10,995 More Info
PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023
PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023SummaryRenal cel...
21 Apr 2016 by Global Data USD $10,995 More Info
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Psoriasis - Global Drug Forecast and Market Analysis to 2024SummaryPsoriasis (PsO) is a...
13 Apr 2016 by Global Data USD $10,995 More Info
PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Bipolar Disorder - Global Drug Forecast and Market Analysis to 2024SummaryBipolar disor...
01 Mar 2016 by Global Data USD $10,995 More Info
PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Hepatitis B Virus (HBV) Therapeutics - Global Drug Forecast and Market Analysis to 2024...
01 Jan 2016 by Global Data USD $10,995 More Info
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024SummaryDry Eye Syn...
05 Nov 2015 by Global Data USD $10,995 More Info
PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Atopic Dermatitis - Global Drug Forecast and Market Analysis to 2024SummaryAlthough the...
03 Nov 2015 by Global Data USD $10,995 More Info
PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023
PharmaPoint: Multiple Myeloma - Global Drug Forecast and Market Analysis to 2023SummaryThe Multiple ...
01 Nov 2015 by Global Data USD $10,995 More Info
PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Multiple Sclerosis - Global Drug Forecast and Market Analysis to 2024SummaryMultiple Sc...
10 Sep 2015 by Global Data USD $10,995 More Info
PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024
PharmaPoint: Allergic Rhinitis - Global Drug Forecast and Market Analysis to 2024SummaryAllergic Rhi...
01 Sep 2015 by Global Data USD $10,995 More Info

This report is published by Global Data

Download Free Report Summary PDF

PharmaPoint: Peripheral Artery Disease - Global Drug Forecast and Market Analysis to 2024 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data